The USFDA sends Lupin an Establishment Inspection Report for its manufacturing plant in Aurangabad
The examination took place between March 6 and March 15, 2024. Based on inspection data, the U.S. FDA has classified the facility as Voluntary Action Indicated (VAI).
The examination took place between March 6 and March 15, 2024. Based on inspection data, the U.S. FDA has classified the facility as Voluntary Action Indicated (VAI).
The multinational pharmaceutical company Lupin Limited (Lupin) said on Tuesday that it has obtained the Establishment Inspection Report (EIR) for its production plant in Aurangabad from the United States Food and Drug Administration (U.S. FDA). The period of the examination was March 6, 2024–March 15, 2024. Based on inspection data, the U.S. FDA has classified the facility as Voluntary Action Indicated (VAI).
We are happy that the U.S. FDA has sent us the EIR with VAI status as a result of their recent inspection of our Aurangabad site. Managing Director of Lupin Nilesh Gupta said, "It is an testimony to our commitment to consistently upholding the highest standards of compliance while supplying high-quality healthcare solutions to patients worldwide."
In the meantime, the company announced in a regulatory filing that the Board of Directors of the Company will meet on Monday, May 6, 2024, among other things, to record and discuss the audited financial results of the Company for the quarter and year ended March 31, 2024, and to recommend any dividends that may be appropriate.
No comments:
Post a Comment